search
Back to results

The Ottawa AF Cardioversion Protocol

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Lifepak 20E Defibrillator, Licence No: 61944
Sponsored by
David Birnie
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation focused on measuring cardioversion, electrical cardioversion, atrial fibrillation, cardioversion protocol

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Documented atrial fibrillation within last 12 months
  • On continuous systemic oral anticoagulation for 28 days prior to the day of cardioversion or must have undergone a recent (< 48 hrs) trans-esophageal echocardiogram prior to the day of cardioversion
  • Able to provide informed consent

Exclusion Criteria:

  • Presence of intracardiac thrombus
  • Pregnancy

Sites / Locations

  • University of Ottawa Heart Institution

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Ottawa AF Cardioversion

Arm Description

elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol

Outcomes

Primary Outcome Measures

Last shock efficacy
Last shock efficacy defined as success ( two or more beats of sinus rhythm) or failure.

Secondary Outcome Measures

Full Information

First Posted
July 11, 2014
Last Updated
September 30, 2019
Sponsor
David Birnie
search

1. Study Identification

Unique Protocol Identification Number
NCT02192957
Brief Title
The Ottawa AF Cardioversion Protocol
Official Title
Developing a Standardized Atrial Fibrillation Cardioversion Protocol
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
August 2015 (undefined)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
April 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
David Birnie

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Atrial fibrillation is an abnormal heart rhythm in which the top chambers of the heart (the atrial chambers) beat very fast. Electrical cardioversion is a technique to convert heart rhythm from AF to normal rhythm. The technique sends out a brief electric shock to the heart through electrodes (paddles or skin patches) applied to the outside of the chest wall. The shock resets the heart rhythm back to its normal pattern. This technique is practiced at many hospitals, including the Heart Institute, and is not experimental. However no detailed national or international guidelines exist to assist physicians in performing cardioversion. Physicians use a variety of methods. Electrical cardioversion does not always restore normal rhythm. Adjusting the electrical energy dose, changing the electrode position and applying pressure to the electrodes may improve the success rate. This study will look at the safety and efficacy of a protocol (step by step method) for electrical cardioversion. The protocol prescribes the electrical energy dose, the electrode position and the application of pressure to the electrodes the physician will use. The individual elements of the protocol (energy dose, electrode position and pressure application) are often used by physician in clinical practice but not necessarily in the step by step order. The purpose of this study is to get all doctors to follow a standard protocol 'the Ottawa AF cardioversion protocol'. We think that using this protocol will improve overall cardioversion success rates. The results of this study may change usual practice in Canada and in other countries. All supplies, equipment and medications used in the protocol cardioversion are approved by Health Canada. We estimate that 389 participants from the University of Ottawa Heart Institute will be enrolled in the study over the next 2 years. The results will be compared with a group of previous patients.
Detailed Description
Study design: All eligible and consenting patients will undergo elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol.The fact that the physician follows the protocol makes this experimental. Aside from following the protocol, subjects will receive standard care before, during and after the procedure. Outcomes of the procedure and clinical features know to affect cardioversion efficacy will be collected. These will be compared to a group of 500 previous patients who underwent elective electrical cardioversion for AF at the Heart Institute. Methodology: The Ottawa AF protocol prescribes the electrical energy dose, the electrode position and the application of pressure to the electrodes the physician will use. The individual elements of the protocol (energy dose, electrode position and pressure application) are often used by physician in clinical practice but not necessarily in the step by step order. The Ottawa AF protocol prescribes the following: the starting energy dose (200 J) and electrode placement (anterior-posterior) the second electrode placement (anterior-lateral) if the first shock is not successful addition of pressure to electrodes if second shock is not successful step up of energy dose (360 J) along with pressure to electrodes if third shock is not successful optional further steps at physician's choice if fourth shock is not successful

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
Keywords
cardioversion, electrical cardioversion, atrial fibrillation, cardioversion protocol

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
389 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ottawa AF Cardioversion
Arm Type
Other
Arm Description
elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol
Intervention Type
Device
Intervention Name(s)
Lifepak 20E Defibrillator, Licence No: 61944
Other Intervention Name(s)
-HEARTSTART XL, Licence No: 24413., -Kendall 1010P Multi-function Defibrillation Electrodes, Licence No: 21857
Intervention Description
Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol. Ottawa AF Cardioversion
Primary Outcome Measure Information:
Title
Last shock efficacy
Description
Last shock efficacy defined as success ( two or more beats of sinus rhythm) or failure.
Time Frame
immediately after cardioversion
Other Pre-specified Outcome Measures:
Title
Adverse Events
Description
adverse events related to cardioversion
Time Frame
participants will be followed for the duration of hospital stay for elective cardioversion, an expected average of 2 hours.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Documented atrial fibrillation within last 12 months On continuous systemic oral anticoagulation for 28 days prior to the day of cardioversion or must have undergone a recent (< 48 hrs) trans-esophageal echocardiogram prior to the day of cardioversion Able to provide informed consent Exclusion Criteria: Presence of intracardiac thrombus Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David H Birnie, MD
Organizational Affiliation
Ottawa Heart Institute Research Corporation
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Ottawa Heart Institution
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4W7
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
30535367
Citation
Ramirez FD, Sadek MM, Boileau I, Cleland M, Nery PB, Nair GM, Redpath CJ, Green MS, Davis DR, Charron K, Henne J, Zakutney T, Beanlands RSB, Hibbert B, Wells GA, Birnie DH. Evaluation of a novel cardioversion intervention for atrial fibrillation: the Ottawa AF cardioversion protocol. Europace. 2019 May 1;21(5):708-715. doi: 10.1093/europace/euy285.
Results Reference
result

Learn more about this trial

The Ottawa AF Cardioversion Protocol

We'll reach out to this number within 24 hrs